Navigation Links
Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial

re permitted to roll over to pegylated interferon plus ribavirin for up to 48 weeks of total treatment; all eligible patients elected to do so.

"These results support our hypothesis that valopicitabine can be administered in combination with pegylated interferon and ribavirin," said Douglas Mayers, M.D., executive vice president and chief medical officer of Idenix Pharmaceuticals. "We are very pleased with the viral kinetics and HCV RNA clearance rates observed in patients treated with triple combination therapy in this study and look forward to further development of this combination."

About Valopicitabine

Valopicitabine is an investigational nucleoside polymerase inhibitor being evaluated in ongoing clinical trials for the treatment of hepatitis C. The most common adverse events reported in valopicitabine clinical trials to date include nausea, vomiting, fatigue, diarrhea, headache, flu-like symptoms and depression. Idenix is developing valopicitabine in collaboration with Novartis Pharma AG.

About Hepatitis C

HCV infection is the most common chronic blood-borne infection in the United States.(1) The Centers for Disease Control and Prevention estimates that 4 million Americans have been infected with HCV, and 2.7 million of these carry chronic HCV infections.(2) Hepatitis C-related liver failure is the most common indication for liver transplantation in the United States.(2) As the prevalence of severe liver disease attributable to hepatitis C rises, deaths due to complications from hepatitis C infection, currently 8,000 to 10,000 per year in the United States, are increasing and are expected to triple by 2010.(3)

Conference Call Information

Idenix will hold a conference call today at 8:30 a.m. EDT. To access the call please dial (800) 774-5358 U.S./Canada or (706) 758-9475 International and enter passcode 3143678 or to listen to a live webcast of the call, go to "Calendar of Events" in the Idenix Investor Center at
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver
2. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
3. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
4. Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
5. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
8. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
9. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
10. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
11. Phase 2 Clinical Results of Ganite Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Post Your Comments:
(Date:7/24/2008)...- Ortho-McNeil Neurologics, a,division of Ortho-Mc...y,that the U.S. Food and Drug Administration (FDA)...(topiramate), based on studies submitted in,respon...the use of TOPAMAX,in pediatric patients aged 1 to...ion to granting pediatric exclusivity, the FDA is ...
(Date:7/24/2008)...ncology Patient Accrual, DENVER, July 24 /PRNewsw...ganization (RMO), has contracted with five leading...site management services for their,clinical trials... The new,trials include the following disease indi...atic Breast Cancer, Metastatic Sarcoma, Chronic My...
(Date:7/23/2008)...y print edition of Clinical C... /- A Roche Diagnostics-sponsored,pil...pe natriuretic peptide,(NT-proBNP) confirms the po... in predicting the risk of cardiovascular adverse ...dal anti-inflammatory drugs of,the COX inhibitor c...
(Date:7/23/2008)...nCode BioPharmaceutics, Inc.,an emerging biopharm...t,results demonstrating the utility of their lead ... chronic blood disorder paroxysmal nocturnal,hemog...ented at the XXII,International Complement Worksho... only treatment currently available for PNH patien...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Cancer researchers seek safe reduction of radiotherapy 2663 1Cancer researchers seek safe reduction of radiotherapy 2663 2New clinical guideline for low back pain 2661 1New clinical guideline for low back pain 2661 2New clinical guideline for low back pain 2661 3Vaginal progesterone gel may improve infant outcomes and 2659 1Vaginal progesterone gel may improve infant outcomes and 2659 2Vaginal progesterone gel may improve infant outcomes and 2659 3Vaginal progesterone gel may improve infant outcomes and 2659 4Drug Combo Helps Fight Marfan Syndrome 2658 1Drug Combo Helps Fight Marfan Syndrome 2658 2
...ERYVILLE, Calif., April 16, 2007 /PRNewswire-First...e mechanism of action of,its anti-cancer agent BZL...ing for late stage breast cancer at the American,A... the Los Angeles,Convention Center in Los Angeles,...ntation will describe the pathway for,cancer cell ...
...USAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 ...from a randomized,double-blind, placebo-controlle... of Aranesp(R) (darbepoetin alfa) for the,treatmen...eiving,chemotherapy or radiotherapy ("the 103 stud... EMEA in these patients. These,results were presen...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7
(Date:7/25/2008)...ON, July 25 /PRNewswire/ -- The Elekta Family of C... treatment solutions at the 2008,American Associat...g,demonstrating how the joint forces of Elekta, I... therapy planning and delivery solutions that,stre...perience for,patients, as well as enhance clinicia...
(Date:7/25/2008)...ds fluid back-up in esophagus can cause immune sys...ay News) -- The first evidence linking gastroesoph...scovered by Duke University Medical Center researc...ns was first noted in the 1970s, and since then st...rcent of asthma patients also experience GERD symp...
(Date:7/25/2008)... The Retina Group of New York will...ted macular degeneration especially designed for s...e Public Library at 116 Merritts Road, Farmingdale.... Attendance is free and refreshments will be prov...6) 939-6100. , Hicksville...
(Date:7/25/2008)... This donation will be used to fac...ve services for children , ... ( www.ivci.com ), a leading integrator of enterp...tion video conferencing, telepresence, audio visua...announced today that it has donated video conferen...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2
...ncer, such as radiotherapy, surgery and drugs as w...edical training// vary throughout the EU, accordin... Medical Oncology (ESMO) on 3 October 2006. Access...om country to country. The survey published in Me...
...ur of daily physical exercise for their future goo...agues at Glasgow University studied 545 children a...red the children who had the recommended adult lev...s, three times a week, reported the online edition...
...al health wards have been graded as unpleasant or ...atients//. The charity called Mind revealed that ...te of repair of their ward while 28% were not sati...Mind is for patients to be treated in a therapeuti...
...erts, some cancer patients are experiencing unjust...te of the new legislation to protect their rights/...fect from the end of last year has provided effect...h severe illnesses like cancer, multiple sclerosis...
Other Medicine News:Health News:Mental Health Wards rated unpleasant 2Health News:Injustice to cancer patients at work 2
Acetate Plate Sealers 100/Box
...croseal 'B' seals provide an adhesive-based sealin...tes. The aggressive adhesive layer ensures secure ...g, and tight sealing during thermal cycling when s...he perforated end-tabs can be removed when using t...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape.
Inquire
Medicine Products: